WuXi PharmaTech and Open Monoclonal Technology (OMT), a provider of novel transgenic animals for development of human therapeutic antibodies, have entered into an agreement to use OMT’s OmniRat to develop therapeutic antibody candidates for commercialization by WuXi’s global customers.   According to the companies, the OmniRat technology generates fully human antibodies with great specificity, affinity and manufacturability and eliminates time-consuming humanization of traditional mouse-derived ...